Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +75

Biogen Zooms on Deal with TJ Biopharma

📈 Biogen stock rose $3.02 (1.7%) on Monday following the announcement of its acquisition deal with TJ Biopharma.

🤝 The companies entered a definitive agreement for Biogen to acquire exclusive rights to felzartamab in the Greater China Region.

🌍 As part of this expansion, Biogen now holds exclusive worldwide rights to felzartamab while it undergoes global Phase 3 clinical studies.

💰 TJ Biopharma will receive an upfront payment of $100 million upon closing the transaction.

💸 The deal includes potential future milestone payments totaling up to $750 million and royalties on net sales in Greater China.

📜 Biogen expects to record the $100 million upfront payment as an expense in the second quarter of 2026.

⚖️ The acquiring company will assume all milestone payment and royalty obligations related to the prior agreement with MorphoSys, a Novartis subsidiary.

💊 Felzartamab is being evaluated for multiple immune-mediated diseases and is described by Biogen as having broad applicability.

🗣️ Fraser Hall, President of Biogen's Intercontinental Region, stated the deal expands the global opportunity for felzartamab.

🚀 Management views the transaction as a significant step to grow their development portfolio in this key market.

📉 The deal is notable because it adds to existing licensing obligations rather than replacing them entirely.

Bullish Signals
  • Biogen stock climbed 1.7% to $180.37 following the announcement of a definitive agreement to acquire TJ Bio's exclusive rights to felzartamab.
  • The deal grants Biogen exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.
  • Biogen will receive a $100 million upfront payment from TJ Bio for the acquisition.
  • TJ Bio is eligible to receive up to $750 million in potential commercial and sales milestone payments, resulting in a total potential consideration of up to $850 million.
  • In addition to milestone payments, Biogen will earn mid-single-digit to low-double-digit percentage royalties on potential net sales in the Greater China Region.
  • Fraser Hall, President of Biogen's Intercontinental Region, described felzartamab as a 'pipeline-in-a-product' with broad applicability across a range of immune-mediated conditions.
Risk Factors
  • The acquisition requires Biogen to record a $100 million upfront payment as an Acquired In-Process Research and Development expense in the second quarter of 2026, indicating significant future capital expenditure.
  • Biogen will assume all existing milestone payment and royalty obligations under the prior MorphoSys licensing agreement for felzartamab, increasing their financial liability burden.
  • The deal is restricted exclusively to the Greater China Region, limiting Biogen's global expansion potential despite claims of worldwide rights.
  • Potential commercial and sales milestone payments are capped at $750 million plus royalties, which may not fully compensate for the upfront investment and assumed liabilities.
  • Felzartamab is still in global Phase 3 clinical studies, introducing the risk of development failure before any commercial revenue can be realized.
Full Analysis
Biogen Inc. (NASDAQ: BIIB) saw its stock price rise on Monday after the company and TJ Biopharma announced a definitive agreement for Biogen to acquire exclusive rights to felzartamab in the Greater China Region. With this new agreement, Biogen now holds worldwide exclusive rights to the drug, which is currently undergoing global Phase 3 clinical evaluations for multiple immune-mediated diseases. The financial terms of the deal specify that TJ Bio will receive a $100 million upfront payment and remains eligible for up to $750 million in potential commercial and sales milestone payments, bringing the total potential consideration to $850 million. Additionally, Biogen will pay mid-single-digit to low-double-digit percentage royalties on potential net sales within the Greater China Region. The upfront payment is scheduled to be recorded by Biogen as an Acquired In-Process Research and Development expense in the second quarter of 2026. Notably, with this transaction, Biogen assumes all milestone payment and royalty obligations previously established under the MorphoSys licensing agreement, with MorphoSys being a wholly-owned subsidiary of Novartis. Fraser Hall, President of Biogen’s Intercontinental Region, stated that the deal is crucial for expanding the global opportunity for felzartamab, describing it as a "potential pipeline-in-a-product" with broad applicability across various immune-mediated conditions. The agreement aims to grow Biogen's development portfolio in this key market. Following the announcement, BIIB shares increased by $3.02, or 1.7%, to reach $180.37.